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Abstract
 
The complement system enhances antibody responses to T-dependent antigens, but paradoxi-
cally, deficiencies in C1 and C4 are strongly linked to autoantibody production in humans. In
mice, disruption of the 
 
C1qa
 
 gene also results in spontaneous autoimmunity. Moreover, defi-
ciencies in C4 or complement receptors 1 and 2 (CR1/CR2) lead to reduced selection against
autoreactive B cells and impaired humoral responses. These observations suggest that C1 and
C4 act through CR1/CR2 to enhance humoral immunity and somehow suppress autoimmu-
 
nity. Here we report high titers of spontaneous antinuclear antibody (ANA) in 
 
C4
 
2
 
/
 
2
 
 
 
mice.
This systemic lupus erythematosus–like autoimmunity is highly penetrant; by 10 mo of age, all
 
C4
 
2
 
/
 
2
 
 females and most males produced ANA. In contrast, titers and frequencies of ANA in
 
Cr2
 
2
 
/
 
2
 
 mice, which are deficient in CR1 and CR2, never rose significantly above those in
normal controls. Glomerular deposition of immune complexes (ICs), glomerulonephritis, and
splenomegaly were observed in 
 
C4
 
2
 
/
 
2 
 
but not 
 
Cr2
 
2
 
/
 
2 
 
mice. 
 
C4
 
2
 
/
 
2
 
, but not 
 
Cr2
 
2
 
/
 
2
 
, mice ac-
cumulate activated T and B cells. Clearance of circulating ICs is impaired in preautoimmune
 
C4
 
2
 
/
 
2
 
, but not 
 
Cr2
 
2
 
/
 
2
 
, mice. C4 deficiency causes spontaneous, lupus-like autoimmunity
through a mechanism that is independent of CR1/CR2.
Key words: complement • autoantibody • glomerulonephritis • splenomegaly • immune 
complex
 
Introduction
 
Systemic lupus erythematosus (SLE)
 
1
 
 is an autoimmune
disease characterized by generalized disturbances in T and
B lymphocytes and inflammatory damage to many tissues
(1, 2). Activated, autoreactive B cells are present in patients
with SLE and produce high titers of serum autoantibody to
nuclear components. Serum antibody to double-stranded
(ds)DNA is an important diagnostic marker for SLE. These
antinuclear antibodies (ANAs) can directly attack tissues or
form immune complexes (ICs) that elicit inflammation and
damage tissues such as the kidney. Either individually or
together, both processes can eventually cause organ failure
(1, 3, 4).
The etiology and pathogenesis of SLE remain poorly un-
derstood. A variety of genetic factors have been linked to
SLE (1, 4, 5), and among these, deficiencies in components
of the classical pathway of complement carry perhaps the
strongest association (1). SLE develops in most individuals
with genetic deficiencies in C1 or C4 (6–9). Although ge-
netic deficiencies in complement are rare, acquired defi-
ciencies in complement components are common (8) and
characteristic of SLE flares in patients (10–12). These ac-
quired deficiencies are presumed to result from the con-
sumption of complement by ICs (10–12); their impact, if
any, in SLE pathogenesis is unknown. Thus, in humans,
components of the classical pathway for complement acti-
vation, especially C1 and C4, may suppress incipient au-
toimmunity.
Recently, a similar role for C1q in suppressing autoim-
munity in mice was demonstrated by Botto et al. (13).
 
C1qa
 
2
 
/
 
2
 
 mice on a mixed B6/129 genetic background
spontaneously produced high titers of ANA, whereas wild-
type controls generated low levels of autoantibody; conse-
quently, 25% of 
 
C1qa
 
2
 
/
 
2
 
 mice also exhibited glomerulone-
phritis (13).
 
How C1q activity suppresses autoimmunity remains un-
known. C1 is the first component in the classical pathway,
and one subunit of C1q associates with two subunits of
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C1r and C1s to form the C1 macromolecular complex
(14). C1q binds to the Fc portions of antibodies com-
plexed with antigen. This binding induces enzymatic ac-
tivity by C1r, leading to the sequential activation of C1s,
C4, and C2 to form the C3 convertase (14, 15). The split
products of C4 and C3 can attach covalently to proteins
(14, 15), and several of these split products—C4b, C4d,
iC3b, C3dg, and C3d—are ligands for the CR1 (CD35)
and CR2 (CD21) complement receptors (16). Signifi-
cantly, C4 often mediates the biological activities of C1.
For example, phagocytosis and lysis of bacteria (17) are
regulated by C1 activity in generating C4 fragments and
the formation of the C3 convertase. This interdependence
suggests that C1q might suppress autoimmunity through a
mechanism also requiring C4, a notion supported by clini-
cal evidence that deficiencies in either C1 or C4 are
strongly linked to SLE (6, 7, 9, 18).
How might C1 and C4 suppress the production of au-
toreactive antibody? Paradoxically, complement promotes
specific immunity to T-dependent antigens (16); B lym-
phocytes express receptors for complement (19), and the
temporary depletion of C3 reduces primary antibody re-
sponses (20). Also, impaired humoral immune responses
are common in individuals with genetic deficiencies in
some complement components (21). Recently, mice defi-
cient in complement C1q, C4, and C3 were shown to
have diminished antibody and germinal center (GC) re-
sponses (22, 23). Diminished antibody and GC responses
are also characteristic of 
 
Cr2
 
 knockout mice that are defi-
cient for CR1 and CR2 (24–26). The observation that
 
C4
 
2
 
/
 
2
 
 and 
 
Cr2
 
2
 
/
 
2
 
 mice generate identical patterns of hu-
moral impairment suggests that C4 enhances B cell re-
sponses via CR1/CR2 (16).
Three dominant models, not mutually exclusive, have
been proposed to explain how C4 interacts with CR1/
CR2 to promote humoral immunity. First, CR1/CR2
may focus complement-decorated ICs to follicular den-
dritic cells, promoting their support of GCs (27–29). Sec-
ond, complement-decorated antigens may bridge the B cell
antigen receptor (BCR) and CR2/CD19 coreceptor to
enhance B cell responses (16, 21, 30). Third, complement-
decorated antigens may aggregate CR2/CD19 complexes
independently of the BCR and elicit CD19 signals that in-
crease B cell responsiveness (31). Similar mechanisms may
operate during the late stages of B cell development in
bone marrow. 
 
Cr2
 
2
 
/
 
2
 
 and 
 
C4
 
2
 
/
 
2
 
 mice do not efficiently
anergize B cells expressing autoreactive BCRs (32), and na-
ive B cells from 
 
Cr2
 
2
 
/
 
2
 
 mice express patterns of V
 
H
 
 gene
segment usage different from 
 
Cr2
 
1
 
/
 
2
 
 controls (26). Simi-
larly, 
 
lpr/lpr
 
 mice bred to be deficient in C4 or CR1/CR2
have accelerated autoimmune disease (32).
These models to explain complement’s (C4) role in en-
hancing humoral immunity and suppressing autoantibody
depend on CR1/CR2. This dependence on CR1/CR2
in systemic autoimmunity is consistent with the observa-
tion that leukocytes from SLE patients express lower
amounts of CR1 and CR2 (33). Similarly, CR1 and CR2
are progressively lost from the surfaces of B cells in MRL/
 
lpr
 
 mice, even before the onset of autoimmune nephritis
(34).
However, if complement’s promotion of humoral im-
munity and suppression of SLE are mediated by CR1/
CR2, the absence of clinical associations between genetic
deficiencies of C3 and SLE (6, 7) is perplexing, as C3 split
products are principal ligands for CR1 and CR2 (16, 21).
Indeed, whereas C3-deficient mice have poor primary an-
tibody responses (16), they exhibit good selection against
autoreactive B cells and no significant acceleration of 
 
lpr
 
-
induced autoimmunity (32). The weak association of C3
deficiency and autoimmunity does not preclude a role for
CR1 and CR2 in self-tolerance, as C4 also generates
ligands for CR1 and CR2 (16). The absence of an associa-
tion does, however, raise the possibility that C4 promotes
autoantibody production independently of CR1/CR2 and
by a mechanism distinct from complement’s immunoen-
hancing activities.
In this study, we demonstrate that 
 
C4
 
2
 
/
 
2
 
 mice achieve
high levels of spontaneous ANA, splenomegaly, and glo-
merulonephritis by 10 mo of age. Complete genetic pene-
trance of C4 deficiency occurs in female mice, but only
two-thirds of age-matched males become autoimmune. In
contrast, 
 
Cr2
 
2
 
/
 
2
 
 mice on the same genetic background did
not produce significant levels of ANA nor exhibit kidney
pathology. Thus, C4 deficiency elicits a lupus-like autoim-
munity in mice by processes that do not depend on CR1
and CR2.
 
Materials and Methods
 
Mice. Cr2
 
2
 
/
 
2
 
 (25) and 
 
C4
 
2
 
/
 
2
 
 (22) mice were originally es-
tablished on the 129/Sv genetic background and subsequently
bred onto a hybrid B6/129, homozygous 
 
Igh
 
b
 
 
 
background as de-
scribed (26). In brief, 
 
Cr2
 
2
 
/
 
2
 
 and 
 
C4
 
2
 
/
 
2
 
 mice were crossed with
C57BL/6 mice (The Jackson Laboratory), and F2 offspring were
typed for 
 
Cr2
 
 or 
 
C4
 
 (22, 25, 26) and 
 
Igh
 
 haplotypes (26). C57BL/6
and 129 mice share identical MHC haplotypes, the locus most
prominently linked to autoimmunity. The two strains differ at
 
Igh
 
: B6 mice are 
 
Igh
 
b
 
 and 129 mice are 
 
Igh
 
a
 
. As heterogeneity at
 
Igh
 
 could alter the potential B cell repertoires in these mice, we
selected only cohorts of B6/129 mice and their littermates carry-
ing mutant 
 
C4
 
 or 
 
Cr2
 
 alleles that were also homozygous for 
 
Igh
 
b
 
.
We designate this background as B6/129.
 
Igh
 
b
 
 or wild type. More
than 10 females and males in each cohort were bred to generate
experimental and control animals. In some experiments, C57BL/6
mice were also used as normal controls. Mice with a mixed B6/
129 genetic background have been used in studies on autoimmu-
nity (13, 35, 36). In some studies, wild-type B6/129 mice exhibit
slightly higher levels of background autoantibody than do B6
mice (13). In others, even old B6/129 mice do not have elevated
levels of autoantibody (35, 36). MRL-
 
Fas
 
lpr
 
 mice were purchased
from The Jackson Laboratory. All mice in this study were main-
tained under specific pathogen–free conditions at the Duke Uni-
versity Medical Center vivarium. Mice were bled at 2, 5–6, or 10
mo of age. All mice were killed at 10 mo of age.
 
Detection of ANA and Antibody Specific for Native DNA.
 
Slides
containing HEp-2 cells and 
 
Crithidia
 
 
 
luciliae
 
 were purchased from
Sigma-Aldrich and Scimedx Corp., respectively. The presence
of IgG ANA and IgG specific for native (n)DNA was deter- 
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mined by reactivity to HEp-2 (37) or 
 
C. luciliae
 
 (38), respec-
tively. Slides were rehydrated in PBS, pH 7.4, blocked with PBS
containing 10% FCS and 0.1% Tween 20 (Sigma-Aldrich), and
then washed with PBS containing 1% BSA and 0.1% Tween 20.
Serum samples were diluted in this washing solution starting at
1:40 and 1:10 for ANA and anti-nDNA, respectively, and incu-
bated with substrates for 1 h at room temperature. Bound serum
IgG was revealed by FITC-conjugated goat anti–mouse IgG
(Sigma-Aldrich). Slides were counterstained with Evans blue
(Sigma-Aldrich), and examined blindly under a fluorescence mi-
croscope. All serum samples that were positive at the starting di-
lution were serially diluted (1:3 for ANA, 1:2 for nDNA) and ti-
trated to endpoints.
 
ELISA for Anti-DNA Antibodies.
 
Double-stranded calf thy-
mus DNA (dsDNA; Sigma-Aldrich) was purified by phenol–
 
chloroform extraction and then treated with S1 nuclease (Life
Technologies) as described (39) to remove single-stranded
(ss)DNA contaminants. To prepare ssDNA, dsDNA was boiled
in water for 10 min and diluted in ice cold 1
 
3
 
 SSC buffer to 50
 
m
 
g/ml. dsDNA was also diluted to 50
 
 m
 
g/ml in 1
 
3
 
 SSC. Diluted
ss- and dsDNA preparations were coated and plates blocked as
described (40–42). Serum samples were diluted 1:100 and incu-
bated on DNA-coated plates for 1 h at room temperature. Each
ELISA plate included a standard of a serially diluted mAb, TG7-
83 (IgG1/
 
l
 
1; from T.F. Tedder, Duke University, Durham,
NC) that avidly binds both ss- and dsDNA. After washing,
bound IgG was revealed by horseradish peroxidase (HRP)-con-
jugated goat anti–mouse IgG (Sigma-Aldrich). HRP activity was
determined and analyzed as described elsewhere (26). The TG7-
83 standard bound immobilized ss- and dsDNA to an endpoint
Figure 1. ANA titers in
Cr22/2,  C42/2, and control
mice at 5–6 (A) or 10 mo (B) of
age. Each point represents a se-
rum sample from an individual
mouse, except for B6.MRL-
Faslpr, which is a serum pool
from three mice. Numbers in
parentheses following the sym-
bols of sex are indicate numbers
of mice. The broken line indi-
cates the cut-off titer (1:40);
placement of data points below
this line does not indicate differ-
ences in titers. 
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concentration of 25 ng/ml. Serum samples were considered posi-
tive if the OD at 1:100 dilution was greater than the TG7-83
endpoint OD on the same plate.
 
Histopathology of Kidney and Spleen.
 
Kidney and spleen sec-
tions were prepared as described (43). Immunohistochemistry for
the detection of T and B cells and GCs in spleen sections has
been described elsewhere (43). To identify IgG and C3 deposi-
tion on kidney sections, acetone-fixed sections were rehydrated
in PBS for 20 min and blocked in PBS, pH 7.4, containing 10%
normal goat serum (Life Technologies) and 0.1% Tween 20. The
sections were then stained at room temperature for 1 h with
FITC-conjugated goat anti–mouse IgG (Sigma-Aldrich) or goat
anti–mouse C3 antibodies (ICN Biomedicals). After staining,
slides were washed, counterstained with Evans blue, and exam-
ined by fluorescence microscopy. Some kidney sections were
postfixed with 1% paraformaldehyde (Sigma-Aldrich), stained
with hematoxylin and eosin (Sigma-Aldrich), and examined by
microscopy. Glomerulonephritis was determined according to es-
tablished criteria (44). Renal function was assessed by measure-
ment of urea nitrogen in serum using a blood urea nitrogen
(BUN) rate kit (Sigma-Aldrich).
 
Flow Cytometry.
 
Splenocyte suspensions were prepared and
blocked for FcR-mediated binding (26). Cells were then stained
with biotinylated antibodies, followed by staining with streptavi-
din and antibodies conjugated with fluorochromes. 7-aminoacti-
nomycin D (7-AAD; Molecular Probes, Inc.) was used to identify
dead cells. The following antibodies/conjugates were used: bio-
tinylated monoclonal anti–Mac-1, -B220, -CD44, or –TCR-
 
b
 
(PharMingen); FITC-labeled monoclonal GL-7, anti–Gr-1,
–TCR-
 
b
 
, or -B220 (PharMingen); PE-conjugated monoclonal
anti-B220 or -Fas (PharMingen); and Red 613–labeled streptavi-
din (Life Technologies).
 
In Vivo Clearance of Circulating ICs.
 
The IgG2b
 
l
 
1 mAb,
P14.2.14 (from Dr. T. Imanishi-Kari, Tufts University, Boston,
MA), which binds (4-hydroxy-3-nitrophenyl)acetyl (NP) with a
 
K
 
a
 
 
 
<
 
 10
 
6
 
 M
 
2
 
1
 
, was used to make ICs. P14.2.14 was mixed with
biotinylated NP
 
16
 
-BSA at a 3:1 molar ratio and incubated at 37
 
8
 
C
for 1 h. After incubation, the reaction mixture was centrifuged at
12,500 
 
g
 
 for 10 min; 
 
,
 
4% of total protein precipitated. Soluble
ICs were injected intravenously into mice. Each mouse received
a preparation of ICs formed with 100 
 
m
 
g of antibodies and 13 
 
m
 
g
of biotinylated NP
 
16
 
-BSA, arbitrarily designated as 100 relative
units (RU). Mice were bled at different times after injection, and
levels of IC in plasma were assessed by ELISA. In brief, streptavi-
din (Sigma-Aldrich) was coated on plates at 10 
 
m
 
g/ml in 0.1 M
carbonate buffer, pH 8.8. Plates were then washed and blocked
with PBS containing 0.1% Tween 20 and 1% BSA. Plasma sam-
ples were serially diluted, added to plates, and incubated for 30
min at room temperature. After washing, bound ICs were re-
vealed with HRP-conjugated goat anti–mouse IgG2b or goat
anti–mouse Ig
 
l
 
 (Southern Biotechnology Associates, Inc.) at
room temperature for 1 h. Plates were then washed, developed,
and analyzed as above.
 
Results
 
C42/2, not Cr22/2, Mice Produce High Titers of Autoanti-
body. Cohorts of C42/2, Cr22/2, and control mice were
examined for IgG ANA. At 2 mo of age, IgG ANA was not
detectable in C42/2 mice (n 5 12) or in age- and sex-
matched wild-type controls (n 5 8). By 5–6 mo of age, low
titers of ANA were occasionally detected (<20%) in B6/
129.Ighb and B6 mice (Fig. 1 A). However, more than half
(9/17) of age-matched, female C42/2 mice had developed
titers of ANA that were comparable to ANA present in sera
pooled from B6.MRL-Faslpr mice (Fig. 1 A). At 5–6 mo,
some male C42/2 mice exhibited higher levels of ANA
than sex-matched controls, but the difference was not statis-
tically significant (P . 0.05; c2 test). Unlike the C4-defi-
Figure 2. Representative staining for IgG ANA and anti-nDNA serum antibody from B6.Ighb (left), Cr22/2 (center), and C42/2 (right) mice. HEp-2
cells were used as substrates for ANA (top panels, 3200 magnification), and C. luciliae were used to detect anti-nDNA antibody (bottom panels, 31,000
magnification). Bound serum IgG was revealed by FITC-conjugated goat anti–mouse IgG (green). Cells were counterstained with Evans blue (red). Ar-
row indicates serum IgG binding to the kinetoplast of C. luciliae, where dsDNA is present in native form.1343 Chen et al.
cient mice, 5–6-mo-old Cr22/2 mice produced only occa-
sional and low levels of serum ANA that could not be
distinguished from that present in control groups (Fig. 1 A).
By 10 mo of age, the incidence of ANA in both wild-
type and Cr22/2 mice increased by an insignificant amount
(P . 0.05, c2 test), and ANA titers remained equivalent in
both groups as well (Fig. 1 B and Fig. 2). C41/2 mice also
exhibited background levels of ANA at 10 mo. In contrast,
significant titers of ANA, some as high as 1:30,000, were
present in all 10-mo-old, female C42/2 mice (Fig. 1 B and
Fig. 2). The majority (14/21) of 10-mo-old male C42/2
mice were also positive for ANA, but ANA titers and the
frequency of ANA1 males were significantly lower than
those of female littermates (Fig. 1 B).
Antibody specific for DNA is a common component of
ANA, and anti-DNA antibody is often used as a diagnostic
marker for SLE (1). Therefore, we screened the sera of
C42/2, Cr22/2, and control mice for the presence of anti-
body specific for ss- and dsDNA by ELISA (40–42) and for
antibody specific for the native form of dsDNA, nDNA
(Fig. 2 and Tables I and II) (38).
In general, the frequencies of reactive sera and specific
IgG titers were highest for ssDNA, followed by dsDNA and
nDNA, respectively. At 5–6 mo of age, only 5% (1/20) of
B6 mice expressed detectable serum titers of any form of
anti-DNA antibody, a frequency too low to determine if
females were more prone to autoantibody production than
males (Table I). Levels of all three types of anti-DNA anti-
body were modestly higher in age-matched B6/129.Ighb
mice than in B6 mice. Anti–ss- and dsDNA antibodies ap-
pear to be more common in female B6/129.Ighb mice (18%;
4/22) than in males (5%; 1/21) (Table I). At 5–6 mo, the
frequency of female (46%; 11/24), but not male (13%; 3/24),
Cr22/2 mice with serum anti-ssDNA IgG was significantly
higher than that of B6/129.Ighb controls. However, fre-
quencies of Cr22/2 mice with serum IgG reactive to ds-
and nDNA did not differ from those in wild-type animals
(Table I). In sharp contrast to the other cohorts of mice,
both the frequencies and titers of anti-DNA IgG were gen-
erally elevated in female and male C42/2 mice. Between
74% (14/19) and 47% (9/19) of 5–6-mo-old female C42/2
mice developed significant levels of IgG antibody specific
Table I. Spontaneous Autoantibody Production in 5–6-mo-old Mice
B6 B6/129.Ighb Cr22/2 C42/2
female male female male female male female male
n 20 15 22 19 24 24 19 17
ANA percent positive* 30 13 18 21 21 21 68 41
Range (titer)‡ 0–360 0–360 0–1,080 0–360 0–360 0–360 0–9,720
0–
9,720
Median 0 0 0 0 0 0 360 0
c2 (P)§ ns ns – – ns ns ,0.005 ns
Anti-ssDNA percent positivei 0 0 18 5 46 13 74 41
Range (mg/ml) 0 0 0–50 0–5 0–14 0–4 0–342 0–48
Median 0 0 0 0 0 0 5 0
c2 (P) ,0.05 ns – – ,0.05 ns ,0.0005 ,0.01
Anti-dsDNA percent positivei 5 0 18 5 25 13 53 29
Range (mg/ml) 0–3 0 0–10 0–6 0–14 0–7 0–350 0–30
Median 0 0 0 0 0 0 3 0
c2 (P) n sn s – –n sn s ,0.05 ns
Anti-nDNA percent positive¶ 0 0 5 5 14 14 47 35
Range (titer) 0 0 0–20 0–10 0–20 0–20 0–80 0–40
Median 0 0 0 0 0 0 0 0
c2 (P) n sn s – –n sn s ,0.005 ,0.05
*End-point titers #1/40. 
‡Samples are arbitrarily assigned a value of zero for statistics purposes if titrated below cut-off values. 
§Compared to age- and sex-matched B6/129.Ighb mice. ns, not significant (P . 0.05). 
iSerum concentration $2.5 mg/ml. 
¶Endpoint titers #1/10.1344 C4 and Spontaneous Autoimmunity
for ss-, ds-, and nDNA (Table I). At 5–6 mo of age, male
C42/2 mice also had increased levels of serum anti-ssDNA
and -nDNA antibody, but the fraction of positive animals
(41%; 7/17, and 35%; 6/17, respectively) and their anti-
body titers were below that of C42/2 females (Table I).
With time, titers of serum autoantibody and the fre-
quency of positive animals increased. These increases are
not significant in 10-mo-old B6, B6/129.Ighb, and Cr22/2
mice but are pronounced in female C42/2 animals (Table
II). Every (38/38) C42/2 female mouse developed IgG
ANA by 10 mo of age, and most also had significant titers
of serum IgG that bound ssDNA (84%; 32/38), dsDNA
(76%; 29/38), or nDNA (58%; 22/38). Autoantibody titers
were also significantly higher in 10-mo-old C42/2 females,
with median concentrations of serum anti-DNA IgG in the
range of <10  mg/ml (Table II). In contrast, 10-mo-old
male  C42/2 mice exhibited only a modest increase in ANA
frequencies and titers and had levels of anti-DNA antibodies
that were not significantly different from controls (Table II).
Autoantibody production by female C42/2 mice is not
an artifact of the mixed genetic background present in these
animals. Significant autoimmunity was not present in either
female or male 10-mo-old C41/2 controls (Table II). Thus,
C4 deficiency alone is capable of inducing a potent autoim-
mune state in B6/129.Ighb mice. Realization of this autoim-
munity is, however, regulated by sex-specific factors.
Although a significantly higher proportion of female
Cr22/2 mice exhibited anti-ssDNA IgG antibody at 5–6
mo (Table I), at 10 mo autoantibody levels in Cr22/2 mice
were not different from B6/129.Ighb controls (Table II).
Thus, the absence of CR1 and CR2 is not sufficient to
cause SLE-like autoimmunity in mice with a genetic back-
ground that is a mix of the B6 and 129 strains.
IC Deposition and Glomerulonephritis in C42/2 Mice.
Consistent with a pattern of SLE-like autoimmunity, 10-
mo-old female C42/2 mice manifest a striking glomerular
pathology with a predominantly mesangial deposition of
IgG and C3 and marked enlargement with hypercellularity
(Fig. 3). This pattern of glomerulonephritis was detected in
half (5/10) of female C42/2 mice, but not in C42/2 males
(0/5). Despite the striking renal histopathology present in
10-mo-old female C42/2 mice, we did not detect compro-
Table II. Spontaneous Autoantibody Production in 10-mo-old Mice
B6 B6/129.Ighb Cr22/2 C41/2 C42/2
female male female male female male female male female male
n 30 20 33 23 23 45 21 20 38 21
ANA percent positive* 30 15 27 35 43 31 38 25 100 67
Range (titer)‡ 0–360 0–120 0–360 0–360 0–1,080 0–360 0–1,080 0–360 120–29,160 0–9,720
Median 0 0 0 000001,080 120
c2 (P)§ ns ns – – ns ns ns ns ,0.00001 ,0.05
Anti-ssDNA percent positivei 13 0 18 13 22 9 10 0 84 29
Range (mg/ml) 0–11 0 0–150 0–32 0–38 0–10 0–4 0 0–286 0–357
Median 0 0 0 00000 1 3 0
c2 (P) n s n s––n sn sn sn s ,0.00001 ns
Anti-dsDNA percent positivei 7 0 15 4 26 7 14 5 76 14
Range (mg/ml) 0–12 0 0–150 0–30 0–55 0–12 0–5 0–3 0–318 0–260
Median 0 0 0 00000 5 0
c2 (P) n s n s––n sn sn sn s ,0.00001 ns
Anti-nDNA percent positive¶ 1 0 0 9 49700 5 8 1 4
Range (titer) 0–20 0 0–20 0–10 0–20 0–20 0 0 0–160 0–80
Median 0 0 0 00000 1 0 0
c2 (P) n s n s––n sn sn sn s ,0.00005 ns
*End-point titers #1/40. 
‡Samples are arbitrarily assigned a value of zero for statistics purposes if titrated below cut-off values.
§Compared to age- and sex-matched B6/129.Ighb mice. ns, not significant (P . 0.05). 
iSerum concentration $2.5 mg/ml. 
¶Endpoint titers #1/10.1345 Chen et al.
mised kidney function. BUN levels in five randomly cho-
sen 10-mo-old female C42/2 and 129/B6.Ighb mice re-
mained within normal ranges (22.5 6 2.5 and 20.4 6 1.6
mg/dl [mean 6 SEM], respectively; P . 0.05, Student’s t
test). C42/2 mice in this BUN test cohort were killed, and
their kidneys were examined histologically; two exhibited
the characteristic glomerular IgG and C3 deposition and
mononuclear cell infiltration (Fig. 3). In contrast to C42/2
mice, cohorts of 10 female Cr22/2 and B6/129.Ighb animals
exhibited normal glomerular structure. Significant deposits
of IgG or C3 were not observed in the kidneys of wild-
type controls and Cr22/2 mice (Fig. 3).
Splenomegaly in C4-deficient Mice. Like other strains of
mice that develop spontaneous, systemic autoimmunity
(45), female C42/2 animals develop splenomegaly. The
spleens of 2-mo-old C42/2 mice (56 6 2 mg, n 5 12) are
no larger than those of wild-type controls (62 6 3 mg, n 5
10). By 10 mo, average spleen weight in B6, B6/129.Ighb,
and C41/2 mice uniformly increased by 40–50% to z90
mg (Fig. 4). The spleens of Cr22/2 mice were comparably
sized at 10 mo of age, with averages of 101 6 6 and 108 6
7 mg/spleen in males and females, respectively (Fig. 4).
However, increases in 10-mo-old female C42/2 mice were
much larger, with an average spleen weight (368 6 64 mg)
about fourfold heavier than that of age-matched controls
(90 6 7 mg; P , 0.0005, Student’s t test). More than two-
thirds (18/26) of 10-mo-old C42/2 female mice had spleen
weights at least twice the wild-type average, and approxi-
mately one-third (8/26) had spleens greater than or equal
to four times larger (Fig. 4). Splenomegaly was present in at
least one 10-mo-old male C42/2 mouse, but as a group,
male C42/2 mice do not exhibit significant splenic enlarge-
ment in comparison to age-matched controls (P . 0.05,
Student’s t test). Indeed, at 10 mo, distributions of spleen
weights in B6, B6/129.Ighb, C41/2, and Cr22/2 mice were
not significantly different (Fig. 4). Lymph nodes and
Peyer’s patches in C42/2 mice appeared comparable in size
to all control groups (data not shown).
Analysis of Splenocyte Populations in C42/2 Mice. To de-
termine if splenomegaly in C42/2 mice resulted from the
expansion of splenocyte populations, we analyzed spleen
cell compartments by flow cytometry. Spleens of 10-mo-
old B6, B6/129.Ighb, and Cr22/2 mice, strains that show
no evidence of splenomegaly (Fig. 4), contain similar
numbers of nucleated cells (average, 114  6  14  3 106;
range, 66–150 3 106). Numbers of nucleated splenocytes
from five randomly chosen 10-mo-old female C42/2 mice
(178 6 40 3 106 per spleen) were moderately (50–60%)
increased over controls, even though spleen weights were
increased an average of 300%. This observation suggests
that vascular congestion plays a significant role in the sple-
nomegaly of C42/2 mice.
Figure 3. Glomerular IC deposition and glomerulonephritis in C42/2 mice. Kidney sections from 10-mo-old, female B6/129.Ighb (left), Cr22/2 (cen-
ter), and C42/2 (right) mice were stained with FITC-conjugated goat anti–mouse IgG (green, top panels, 3200 magnification) or goat anti–mouse C3
(green, center panels, 3200 magnification) and counterstained with Evans blue (red). Glomerular cellularity was examined in sections stained with hema-
toxylin and eosin (bottom panels, 3400 magnification). G, glomerulus; T, tubule.1346 C4 and Spontaneous Autoimmunity
Spleens from C42/2 and wild-type mice have compara-
ble numbers of B2201 B cells (77 6 23 3 106 versus 63 6
8 3 106, respectively) and TCR-b1 T cells (33 6 8 3 106
versus 30 6 2 3 106) (Table III). However, macrophage
(Mac-11Gr-12) and neutrophil populations (Mac-11Gr-
11) (46) were, respectively, two- and fourfold larger in
C42/2 animals than in age-matched controls (Table III).
This increase in inflammatory cells was not evident in
Cr22/2 mice.
Whereas the numbers of splenic lymphocytes in C42/2
mice do not differ from controls, T and B cell populations
in 10-mo-old C42/2 mice show evidence of cellular activa-
tion by increased expression of CD44, Fas, or GL-7 (Fig. 5
and Table III) (47). This activation is not constitutive in
C42/2 animals, as frequencies of activated lymphocytes in
2-mo-old C42/2 mice are not significantly different from
age-matched B6/129.Ighb controls (Table III). Notably, GL-7
is a marker of GC B cells (48), and we indeed detected
spontaneous GC formation in the spleens of C42/2 mice by
immunohistochemistry (Chen, Z. and G. Kelsoe, unpub-
lished data). This observation implies a role for the GC reac-
tion in the production of autoantibody in these mice (49).
Figure 4. Mice deficient in
C4 exhibit splenomegaly. Mice
at 10 mo of age were killed and
their spleens weighed. The bro-
ken line indicates 2 SD above
the average weight of spleens in
all B6, B6/129.Ighb, and C41/2
mice. *P , 0.0005, Student’s t
test.
Table III. Flow Cytometric Analysis of Splenocytes
B6 B6/129.Ighb Cr22/2 C42/2
Age (mo) 10 2 10 10 2 10
Percent TCR-b1 23.33 6 2.30 (ns) 35.45 6 0.45 26.53 6 1.53 29.23 6 2.01 (ns) 37.65 6 3.18 (ns) 19.06 6 1.82 (,0.01)
Percent B2201 55.03 6 0.96 (ns) 47.40 6 2.83 55.15 6 1.15 48.98 6 4.00 46.05 6 3.18 (ns) 44.16 6 6.50 (ns)
Percent MAC1Gr-12 6.85 6 0.32 (ns) 7.70 6 0.84 6.09 6 0.33 6.57 6 0.58 (ns) 7.07 6 0.70 (ns) 11.79 6 1.12 (,0.005)
Percent MAC1Gr-11 2.47 6 0.23 (,0.05) 1.86 6 0.14 1.83 6 0.21 2.05 6 0.22 (ns) 2.03 6 0.41 (ns) 6.57 6 2.09 (,0.05)
Percent TCR-b1CD44high 13.20 6 0.87 (ns) 5.88 6 1.42 12.30 6 0.24 9.65 6 0.19 (,0.01) 5.20 6 1.46 (ns) 16.58 6 1.34 (,0.05)
Percent TCR-b1GL-71 0.52 6 0.13 (ns) 0.26 6 0.06 0.30 6 0.01 0.24 6 0.03 (ns) 0.24 6 0.10 (ns) 1.56 6 0.28 (,0.005)
Percent TCR-b1Fas1 2.04 6 0.19 (ns) 0.51 6 0.09 1.62 6 0.22 1.64 6 0.19 (ns) 0.56 6 0.14 (ns) 7.67 6 0.93 (,0.0005)
Percent B2201CD44high 1.59 6 0.18 (ns) 1.52 6 0.23 1.33 6 0.09 0.91 6 0.09 (,0.01) 0.96 6 0.11 (ns) 2.34 6 0.41 (,0.05)
Percent B2201GL-71 1.27 6 0.34 (ns) 0.45 6 0.11 0.67 6 0.07 0.46 6 0.10 (ns) 0.42 6 0.10 (ns) 2.63 6 0.84 (,0.05)
Percent B2201Fas1 0.31 6 0.05 (ns) 0.12 6 0.01 0.23 6 0.03 0.26 6 0.03 (ns) 0.13 6 0.02 (ns) 0.84 6 0.14 (,0.005)
Percentage of TCR-b1, B2201, Mac-11Gr-11, or Mac-11Gr-12 cells are enumerated on a gate of live (7-AAD2) cells. All of the other calculations
are on a live lymphocyte gate. P values (Student’s t test, compared to age-matched B6/129.Ighb mice) are shown in parentheses; ns, statistically not
significant (P . 0.05) in comparison to age-matched B6/129.Ighb mice. Data represent the mean 6 SEM from four to five mice at the age of 10 mo
and two mice of 2 mo in each group, randomly chosen from two to three independent litters. All mice are female.1347 Chen et al.
Impaired Clearance of ICs in C42/2 Mice. Complement
is implicated in the clearance of ICs (8). Walport et al. (8)
have proposed that autoimmunity in complement-deficient
patients might result from failure to clear immunogenic
ICs. Thus, we tested the role of C4 in the clearance of sol-
uble ICs in vivo at an age (2 mo) when C42/2 mice show
no apparent signs of autoimmunity. Cohorts (n 5 2–6) of
2-mo-old C42/2, C41/2, Cr22/2, and B6/129.Ighb mice
were injected intravenously with 100 RU of soluble ICs.
Levels of IC in plasma (z30 RU/ml) were comparable in
all groups at 2 min after injection (Fig. 6). From 2 to 10
min, IC concentrations in plasma decreased about threefold
in C41/2, Cr22/2, and wild-type mice; plasma IC levels in
C42/2 mice, however, remained almost constant during
this period. After 10 min, clearance rates were identical in
all groups, including C42/2. The initial delay in IC clear-
ance by C42/2 mice resulted in a persistent, two- to three-
fold increase in circulating IC levels over that of Cr22/2
mice and B6/129.Ighb controls. Higher levels of ICs in
C42/2 mice remained for as long as 70 min after IC admin-
istration (Fig. 6). Rapid clearance of ICs in Cr22/2 mice
suggests that CR1/CR2 plays a minor role in eliminating
this type of IC from the blood circulation.
Though unlikely, C4 binding to ICs could shield
epitopes recognized by the goat anti–mouse IgG detector
antibody and consequently reduce the apparent levels of
plasma ICs in C4-sufficient mice (Fig. 6). Thus, we re-
peated the measurements of IC levels using a detector anti-
body specific for mouse l L chain; IC clearance rates were
virtually identical to those detected by anti-IgG (Fig. 6, in-
set). IC clearance was similarly impaired in both female and
male C42/2 mice (data not shown), implying that if high
levels of ICs can break self-tolerance (8), gender-specific
factors control the onset of pathological autoimmunity.
Discussion
How does the absence of complement components that
enhance humoral immunity promote the production of au-
toantibody? The conundrum of complement deficiencies
causing SLE is so paradoxical (50) that the role of comple-
ment per se has been questioned (51). It has been proposed
Figure 5. Increased frequencies of activated
T and B cells in spleens of C42/2 mice. Spleno-
cytes from 10-mo-old female B6/129.Ighb (left),
Cr22/2 (center), and C42/2 (right) mice were
analyzed by flow cytometry. Profiles are gener-
ated from a gate for live lymphocytes and are
representative of four to five mice in each
group (see Table III).1348 C4 and Spontaneous Autoimmunity
that the genetic association of C4 and C2 with lupus only
reflects the linkage of polymorphic MHC class I and II
genes to the C4 and C2 genes (51). This proposal is not
supported by the fact that systemic autoimmunity develops
in the majority of patients with defective C1q, a locus not
linked to the MHC (52). Furthermore, C1qa knockout
mice with a hybrid B6/129 genetic background develop
spontaneous autoimmunity, providing direct evidence that
C1q deficiency results in the loss of self-tolerance (13). In
this study, we demonstrate that C42/2 mice, in contrast to
control animals with the same genetic background, sponta-
neously produce ANA and DNA-specific autoantibody
and exhibit histologic glomerulonephritis in an age- and
sex-dependent manner. The H-2b haplotype and the ge-
netic background of B6/129.Ighb stock are permissive for a
humoral autoimmunity caused by C4 deficiency.
The autoantibody in C4-deficient mice is similar to that
characteristic of SLE, and the genetic penetrance of autoim-
munity in C42/2 mice displays the strong bias for females
present in SLE. Case reviews of patients with genetic defi-
ciencies in C4 reveal that 92% (11/12) of C4-deficient fe-
males, in contrast to 44% (4/9) of males, were also diag-
nosed with SLE (6, 7). These values are remarkably similar
to the frequencies of 10-mo-old female and male C42/2
mice with ANA (Table II). Factors that segregate with gen-
der modify the suppressive effect of C4 on autoimmunity in
both humans and mice (Figs. 1 and 4 and Tables I and II).
In the absence of significant autoimmunity in Cr22/2
mice (Figs. 1–3 and Tables I and II), we conclude that C4
inhibits autoimmunity through a mechanism independent
of CR1 and CR2. Cr22/2 mice do not produce levels of
serum ANA or anti-DNA antibody significantly above that
of normal controls, they have histologically normal kid-
neys, and they exhibit no splenomegaly or evidence for
generalized T and B cell activation (Figs. 1–5 and Tables
I–III). These observations are inconsistent with models of
autoimmunity that rely on the ability of the CD19/CR2/
CD81 coreceptor complex to regulate self-reactive B cells
(16, 32, 50). In the absence of strong BCR signals, autore-
active B cells in the bone marrow of Cr22/2 mice might
not encounter sufficient antigen concentrations to affect
negative selection by apoptotic deletion, receptor revision,
or anergy (50). Indeed, the repertoire of peripheral B cells
is altered even in Cr22/2 mice with genetic backgrounds
that do not promote autoimmunity (26). However, our ex-
periments indicate that the presence of self-reactive B cells
is not sufficient for the development of humoral autoim-
munity.
What could account for the activation of self-reactive B
cells in C4-deficient individuals? Deficiencies in C1q and
C4 render mice less able to clear apoptotic cells/debris (13,
53), and C1 was located on the surfaces of apoptotic cells
(54). Botto et al. (13) have reported accumulations of TdT-
mediated dUTP-biotin nick-end labeling (TUNEL)1 cells
in histologically normal glomeruli in C1qa2/2 mice. Phago-
cytosis of apoptotic cells by human macrophages is en-
hanced by complement-containing sera (55). Mevorach et
al. (56) found that apoptotic materials are immunogenic and
accelerate the production of autoantibody in mice not
prone to autoimmunity. However, the significance of the
immunogenicity of apoptotic debris is clouded by reports
that phagocytosis of apoptotic cells by dendritic cells ren-
ders them tolerogenic (57, 58). Nonetheless, apoptotic cel-
lular debris, especially if associated with microbial products
in the form of ICs (18), might activate autoreactive T and B
lymphocytes and induce serum antibody specific for self-
antigens. Indeed, nucleosome-specific, CD41 T cells have
been identified in lupus-prone mice. Moreover, immuniza-
tion with nucleosomes enhanced autoantibody production
(59).
Complement also acts in the clearance of ICs (18). Our
work shows that the clearance of circulating ICs is delayed
in C42/2 mice even before the onset of detectable au-
toimmunity (Fig. 6). Although most ICs were eventually
removed from circulation in the absence of C4 (Fig. 6),
perhaps by Fc receptors (60, 61), levels of ICs remained
modestly elevated in C42/2 mice for as long as 70 min.
With time, this delay could cause significant accumula-
tions of ICs.
Figure 6. Impaired clearance of ICs in C42/2 mice. Cohorts of B6/
129.Ighb (r), Cr22/2 (j), C41/2 (s), and C42/2 (d) mice were each in-
jected with 100 RU of ICs through tail veins and bled from orbital sinus
at 2, 10, 30, 50, or 70 min after IC injection. IC levels in plasma were as-
sessed by ELISA. Data in the figure were determined with a goat anti–
mouse IgG2b detector antibody; inset data were determined with goat
anti–mouse Igl. Upper curves represent the kinetics of IC clearance in
C42/2 mice, and lower curves are average clearance rates by B6/129.Ighb,
C41/2, and Cr22/2 mice; these values do not differ significantly from
each other (P . 0.05; Student’s t test). Individual clearance curves for
B6/129.Ighb, C41/2, and Cr22/2 mice are not shown, but IC RU (mean 6
SEM) values for each group are presented; each point represents two to
six mice. At the time points of 10, 30, 50, and 70 min, IC levels in C42/2
animals differ significantly from B6.Ighb mice (P , 0.05, Student’s t test).1349 Chen et al.
Several plausible consequences of diminished IC clear-
ance in C42/2 mice come to mind. First, excessive IC dep-
osition could cause inflammatory damage, especially in
blood-filtering organs such as kidney and spleen (Fig. 3).
Second, inflammatory damage might expose cryptic au-
toantigens and activate destructive T and B lymphocytes
(8). Third, abundant ICs might enhance antigen uptake
and activation by antigen-presenting cells, promoting lym-
phocyte activation, release of inflammatory cytokines, and
the abrogation of anergy (8, 18). Guinea pigs deficient in
C4 exhibit delayed clearance of particulate ICs (62) and
manifest signs of polyclonal B cell activation and a high in-
cidence of IgM rheumatoid factors (63). The blood-filter-
ing function of the spleen may localize IC-induced inflam-
mation, explaining the absence of hypertrophy in lymph
nodes and Peyer’s patches. ICs and/or the inflammation
they induce might also account for the activation of T and
B cells in C42/2 mice (Fig. 5 and Table III).
What mediates the role of C4 in immune clearance and
autoimmunity? Only deficiencies in C1 (6, 7, 9, 13, 18), C4
(6, 7, 9; Fig. 1–3, Tables I and II), and, to a lesser extent,
C2 (6, 7), are strongly associated with spontaneous autoim-
munity. In contrast, C3 deficiency does not significantly
predispose to autoimmunity in either humans (6, 7) or mice
(32). Thus, do C1 and C4 inhibit autoimmunity via their
tandem roles in the classical pathway of complement activa-
tion or do they act independently? C1 and C4 could act
through a receptor(s) for C4 split products, with C1 cata-
lyzing the formation of C4 ligands. Two complement re-
ceptors are known to bind C4 fragments, CR1 and CR2
(16). Human CR1 participates in IC clearance; ICs are
trapped by CR1 on erythrocytes and transported to the
liver and spleen where they are phagocytosed by reticu-
loendothelial cells (18). C1q and C4b cooperatively increase
immune adhesion mediated by human CR1 (64). How-
ever, human CR1 contributes little to the phagocytosis of
apoptotic cells by macrophages in vitro (55). In our study,
mice deficient in CR1 and CR2 clear soluble ICs normally
(Fig. 6). This observation carries the caveat that mice have
two functional homologues of human CR1, murine CR1
and Crry (65). The crry product is proposed to function as a
regulatory protein (65), but its homology to CR1 suggests
that it might substitute for CR1 in Cr22/2 mice.
If not CR1, CR2, or Crry, what other molecules could
mediate the inhibition of autoimmunity by C4? C3-bind-
ing proteins distinct from CR1 and CR2 are present on
mouse neutrophils and platelets. Although the identities
and function(s) of these proteins are not characterized, they
may mediate CR1/CR2-independent adherence of ICs.
Whether they bind C4 fragments is unknown (66). Re-
cently, CR3 and CR4, but not CR1, were shown to en-
hance phagocytosis of apoptotic cells (55). However, the
primary ligand for CR3 and CR4 is iC3b (67). As C3 is
not associated with autoimmunity (6, 7, 32), it is unlikely
that CR3 and CR4 are. Alternatively, candidate C1q re-
ceptors (68), including the recently cloned C1qRP (69),
might affect IC clearance in vivo and thereby inhibit au-
toimmunity. If this were the case, the association of C4 de-
ficiency and autoimmunity could be explained by the abil-
ity of C4 (and perhaps C2) to anchor/stabilize C1 ligands
on ICs and/or apoptotic cell debris and promote their ad-
hesion (14, 15, 64). This hypothesis could explain the or-
dered relationship C1.C4.C2 of deficiencies in compo-
nents of the classical pathway and risk for SLE (6–8, 18).
However, no direct evidence indicates whether these mol-
ecules act sequentially or independently to suppress hu-
moral autoimmunity.
We propose a “multiple hit” hypothesis for the induc-
tion of humoral autoimmunity in C42/2 mice. First, C4
deficiency may promote autoimmunity by impairing selec-
tion against autoreactive, immature/transitional B cells in
the bone marrow; evidence suggests that this effect on the
B cell repertoire is mediated by CR1/CR2 (32). However,
this altered B cell repertoire alone does not lead to serum
autoantibody (Figs. 1 and 2 and Tables I and II), although it
may accelerate incipient loss of self-tolerance (32). Thus,
C4 also acts independently of CR1 and CR2 to promote
systemic autoimmunity (Figs. 1–3 and Tables I and II).
This effect becomes pronounced with aging and is moder-
ated by sex-linked factors (Figs. 1 and 2 and Tables I and
II). A plausible cause of autoimmunity in C4- and perhaps
C1-deficient animals is impaired clearance of apoptotic cell
debris (53, 55) and ICs (Fig. 6; reference 8). Accumulation
of these potential immunogens might break tolerance and
activate humoral responses to self-components.
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